Turkish Rhubarb

Rhubarb anthraquinone: Topo-II/DNA ↑/↓, apoptosis ↑; preclinical in breast/colorectal/ovarian/pancreatic.

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Strong mechanistic and in vivo signals; anticancer clinical trials are limited.Rheum palmatumRhubarb rootDa Huang

Forms: Root extract capsules (500 mg standardized anthraquinones) · Tincture (1:5, 1-2 mL doses)

Educational only, not medical advice. OncoForge makes no claim that Turkish Rhubarb treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Anthraquinones (emodin, rhein) intercalate DNA and inhibit Topo II, provoking DNA damage and apoptosis in models; also exerts laxative effects useful for cycle-based dosing. Human anticancer efficacy remains preliminary.

Evidence at a glance

Tier 1 · labBreastColorectalOvarianPancreatic

Preclinical Topo II/apoptosis robust; no oncology trials; laxative data strong; ongoing safety in herbal combos.

How it may work

Emodin/rhein insert between DNA base pairs and inhibit topoisomerase II, stabilizing cleavage complexes → DSBs and apoptosis (caspase activation, G2/M arrest). Additional effects include ROS modulation and NF-κB/PI3K-Akt downshift. As anthraquinone laxatives, they increase intestinal secretion and motility.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Topo-II↓Cleavage complex stabilization
DNA Intercalation↑Base pair insertion
Laxative↑Intestinal motility enhancement
Apoptosis↑Caspase activation post-DSB
NF-κB/PI3K-Akt↓Survival signaling suppression

Topo-IIDNA IntercalationLaxative

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Doxorubicin: Topo II synergy in breast models.
Cisplatin: DNA damage amplification in ovarian.
Curcumin: NF-κB co-suppression in colorectal.
Resveratrol: Apoptosis boost in pancreatic.

Overlapping mechanisms

Topo-II ↓: Overlaps etoposide; monitor QT.
Laxative: Redundant with senna; GI fatigue.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Electrolyte ImbalanceGi DiarrheaOxalate Kidney

Potential interactions

diureticsMonitorModerateTheoreticalElectrolyte loss additive.
chemo (topo poisons)SynergizeLowTheoreticalEnhanced DNA damage.
DoxorubicinSynergizeLowTheoreticalTopo II co-inhibition in breast.

Timing

Evening: Aligns with laxative action.
Cyclic: 3-5 days/week to avoid tolerance.

References

Research

No published studies for Turkish Rhubarb yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Turkish Rhubarb depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 250–1000 mg/day (po) Cyclic (3-5 days/week); with meals, Laxative 500 mg/day; preclinical anticancer 200-500 mg/kg; short cycles to prevent dependence; hydrate well..

Trials studying Turkish Rhubarb

1 recruiting on ClinicalTrials.gov. Recruiting is not the same as proven. Search ClinicalTrials.gov →

A Study of Herbal Supplements in Cancer Survivors With Constipation
NCT07091084Recruiting

Trials studying Turkish Rhubarb

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar